Home › Clinical Trials › Find A Research Study

Find A Research Study

Study Title: Liver Cancer (Hepatocellular Carcinoma): Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable (Advanced or Metastatic) Liver Cancer
Category: Cancer, General

Currently accepting participants?
Not at this time.

Principal Investigator: Thomas Malpass
Study Coordinator: Andrea Jacks
Phone: 206-341-1044
Email: andrea.jacks@vmmc.org

What is the Liver Cancer (Hepatocellular Carcinoma): Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable (Advanced or Metastatic) Liver Cancer study?

Please visit clinicaltrials.gov and enter the ID NCT00699374 Or contact the study coordinator.

Who can participate?

Men or women 18 years of age or older with locally advanced or metastatic hepatocellular carcinoma. Other criteria apply, please speak with the study doctor or coordinator.

Study Summary:

The study will evaluate the efficacy and safety of sunitinib (Arm A), given at 37.5 mg orally once daily, compared to sorafenib (Arm B), given orally at 400 mg twice daily, in patients with inoperable liver cancer. A total number of 1200 patients will be enrolled, 600 on Arm A and 600 on Arm B. Study treatment may be adjusted based on patient tolerance. and will be given until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. After discontinuation of study treatment, patients will be followed up in order to collect information on further antineoplastic therapy and survival.

Detailed Study Description:

(No information)

Study Design: Interventional
Phase of Study: Phase III
Study Type: Interventional
Condition or Study Focus: Cancer
Intervention Type: Drug
Intervention Name: Sunitnib vs. Sorafenib
Gender: Male and Female
Age group: Interventional
Sponsor: Pfizer


Other studies in this category include:

Studies currently accepting study participants:

Studies currently not accepting study participants: